Leighl NB, Hellmann MD, Hui R, et al. KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab. J Clin Oncol. 35, 2017 (suppl; abstr 9011).
Dabrafenib plus trametinib bij BRAF-V600E-gemuteerde zeldzame tumoren
jun 2023 | Hoofd-halsoncologie, Leukemie, Maag-darm-leveroncologie, MM, Neuro-oncologie